



AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:


i)



ii)




iii)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amdt. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752


iv)




v)




vi)




vii)




viii)




ix)



2. (Previously Presented) A compound according to Claim 1 having the following stereochemical formula:




3. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:

i)


Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752




ii)




iii)



iv)




v)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752


vi)




vii)




viii)




ix)



x)




4. (Previously Presented) A compound according to Claim 2 having the following stereochemical formula:




5. (Previously Presented) A composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:

i)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752


ii)




iii)




iv)



v)




vi)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752


vii)



viii)




ix)




B) one or more excipients.

6. (Previously Presented) A composition according to Claim 5 wherein said cyclic peptides have the following stereochemical formula:




7. (Previously Presented) A composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)




viii)



ix)




x)




B) one or more excipients.

8. (Previously Presented) A composition according to Claim 7 wherein said cyclic peptides have the following stereochemical formula:




9. (Currently Amended) A method of stimulating the melanocortin-4 (MC-4) receptor in a mammal comprising administering to a mammal in need thereof a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the MC-r receptor, said for treating obesity, said method comprising the step of contacting a human or higher mammal with a composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:

i)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amdt. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752


ii)




iii)



iv)




v)




vi)


Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752




vii)



viii)




ix)




B) one or more excipients.

10. (Currently Amended) A method for suppressing appetite in a human who is endeavoring to reduce caloric intake comprising administering to said human a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the melanocortin-4 receptor, said treating obesity, said method comprising the step of contacting a human or higher mammal with a composition comprising:


A) one or more cyclic peptides having the formula:




i)



ii)




iii)




iv)


Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752




v)




vi)



vii)




viii)




Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amtd. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752

ix)



x)



B) one or more excipients.